Yet GSK is clearly healing from its multiple comorbidities — the worst of which was the (now largely resolved) legal overhang related to heartburn medicine Zantac. Chief executive Emma Walmsley also ...

As global markets navigate a landscape of fluctuating interest rates and geopolitical uncertainties, investors are keenly observing the impact on stock indices worldwide. With U.S. corporate earnings ...

GSK PLC (GSK) is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported. The company is in the healthcare space and there has been a lot of press ...

Zacks Equity Research shares Kratos Defense & Security Solutions KTOS as the Bull of the Day and GSK PLC GSK as the Bear of ...

A task force has been set up to look into how to spend a £2m GSK legacy as the pharmaceutical giant closes its doors in Ulverston. Giles ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...